Pacific Biosciences of California, Inc. (PACB)
Lost Money on Pacific Biosciences of California, Inc.(PACB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences Of California Inc Is Being Investigated For Securities Law Violations And Impacted Investors Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacific Biosciences of California, Inc. (PACB) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
A Securities Fraud Inquiry Has Been Opened Into Pacific Biosciences Of California And The Schall Law Firm Urges Shareholders To Join
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Shareholders of an Investigation into Pacific Biosciences of California, Inc. (PACB) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
The Schall Law Firm Is Investigating Pacific Biosciences Of California For Securities Law Violations And Investors Are Invited To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATTENTION PACB SHAREHOLDERS: Investors who lost money on Pacific Biosciences of California, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
A Securities Fraud Inquiry Into Pacific Biosciences Of California Inc Has Been Launched By The Schall Law Firm And Stockholders Should Join
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences Of California Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Wants Investors To Take Part
LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Inquiry Into Pacific Biosciences Of California Inc For Securities Fraud Has Been Opened By The Schall Law Firm And Stockholders Are Invited To Join
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Pacific Biosciences of California, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - PACB
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
The Schall Law Firm Is Investigating Pacific Biosciences Of California Inc For Possible Securities Law Violations And Investors Are Encouraged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
